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Abstract 
 Dupuytren’s Disease (DD) is a benign fibrosis of the palmar fascia, the connective tissue 
beneath the skin of palm and digits. DD leads to loss of hand function and affects 4 - 6% of the 
US population alone. Current treatments focus on removing diseased tissue through surgery —
however, post-surgery disease recurrence rates exceed 30% with no known cure. Previous 
studies found that fibroproliferative diseases such as DD contain fibroblasts with abnormally 
high levels of β-catenin, similar to certain malignancies such as colon cancer. In colon cancer 
cells, nuclear translocation of β-catenin trans-activates genes responsible for cellular 
proliferation, and this process is facilitated by the transducin β-like proteins TβL1 and TβLR1 
that are post-translationally modified with small ubiquitin-like modifiers (SUMOylation). The 
anti-cancer drug, BC2059 (Tegavivint), has been developed to competitively inhibit interactions 
between β-catenin and SUMOylated TβL1/TβLR1 and is currently undergoing Phase-I clinical 
trials. It is currently unknown whether the SUMOylated TβL1/TβLR1 complex mediates β-
catenin nuclear translocation in DD. In this study, we investigated whether β-catenin interactions 
with SUMOylated TβL1/TβLR1 were present in primary fibroblasts derived from patients with 
DD, and if cytokine treatments mimicking inflammation during fibrosis modified these 
interactions. Through western blotting, proximity ligation assays, and confocal microscopy, we 
confirmed that in DD fibroblasts— the levels of SUMOylated TβL1/TβLR1 increased in 
response to cytokines. Moreover, we observed that the interactions between β-catenin and 
TβL1/TβLR1 were significantly increased. The novel finding of cytokine-induced SUMOylation 
of TβL1/TβLR1 presents a mechanistic link between inflammation and fibroproliferation. Given 
the prevalence and debilitating nature of DD, there exists a need to identify new therapeutic 
	 4	
targets to prevent disease progression and recurrence — the results of this study identify 
SUMOylated TβL1/TβLR1 interactions with β-catenin as a feasible target and provide a strong 
rationale to cross-purpose anti-cancer drugs such as BC2059 to treat DD. 
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Introduction  
Dupuytren’s Disease 
 Dupuytren’s Disease (DD) is a chronic, heritable fibrosis of the palmar fascia —the 
fibrous layer of connective tissue found underneath the skin of the palm and digits.  During the 
progression of DD, the palmar fascia undergoes excessive deposition of collagen, eventually 
thickening to the point where some patients experience permanent hand and/or finger 
contractures1. The prevalence of DD is estimated to be up to 7% in the United States of America, 
and as high as 32% in some regions of Europe2, 3. Current treatments for DD primarily focus on 
directly removing diseased palmar fascia, either through invasive surgical interventions 
(fasciectomy), or enzymatic breakdown using minimally invasive collagenase injections1, 4. 
Unfortunately, post-surgery disease recurrence rates are high, typically exceeding 30% and as a 
result, DD is presently incurable5. Given the prevalence and debilitating nature of DD, there 
exists a crucial need to identify new therapeutic targets in order to prevent disease progression 
and recurrence. 
 
Canonical β-catenin signalling 
 Although DD is ultimately benign, it shares certain molecular characteristics with 
malignant tumours, particularly increased β-catenin levels 6. β-catenin is a dual function trans-
activating factor that regulates gene transcription and coordinates cell-to-cell adhesion7. It is 
normally under regulation and tagged for degradation through phosphorylation through a 
destruction complex consisting of the scaffolding proteins Axin, Adenoma Polyposis Coli 
(APC), glycogen synthase kinase 3β (GSK3β), and casein kinase 1 (CK1). Ultimately, 
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phosphorylated β-catenin undergoes degradation through the 26S proteasome ubiquitination 
pathway 7. Inactivation of the destruction complex occurs canonically through Wnt-signalling, 
where β-catenin accumulates in the cytoplasm and translocates into the nucleus to trans-activate 
genes involved in cell proliferation, differentiation, and adhesion— normally, this process is 
crucial in normal embryonic development7. However, abnormal Wnt-signalling has been 
implicated in various malignancies such as colon cancer as a result of mutations in the APC gene 
—leading to a dysfunctional destruction complex and over-accumulation of β-catenin in the 
cytoplasm6, 7.  
 
The role of β-catenin in normal and abnormal wound healing 
Fibroproliferative diseases such as DD are an exaggerated response to wound healing7. In 
addition to its role in the development of certain cancers, β-catenin is involved in the normal 
wound healing process, which can be characterized by three major phases: the inflammatory 
response, the proliferative phase, and the remodelling phase7 (Figure 1). The inflammatory 
response is necessary to mediate the break down of debris and clearance of bacteria by 
neutrophils and macrophages. To begin the transition from the inflammatory phase to the 
proliferative phase, a number of growth factors and anti-inflammatory cytokines such as 
transforming growth factors α and β (TGFα and TGFβ), epidermal growth factor (EGF), and 
insulin-like growth factor (IGF) are released by macrophages at the wound to stimulate fibroblast 
migration and proliferation. During the proliferation phase, recruited fibroblasts differentiate into 
myofibroblasts, which then function during the tissue-remodelling phase to deposit collagen 
bundles that compact or contract the wound. Notably, within the proliferative phase of normal 
wound healing — it is believed that TGFβ mediates β-catenin signalling in fibroblasts through 
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inactivation of GSK3β, and that fibroblast proliferation and subsequent tissue remodelling is 
dependent on β-catenin signalling. Ultimately, dysregulation of β-catenin-signalling during 
fibroblast proliferation may be a factor in the abnormal wound healing response leading to the 
development of fibroproliferative disorders such as DD 16, 17, 18. 
 
Previous studies have shown that the fibroblasts inducing palmar fascia fibrosis (DD 
fibroblasts) exhibit markedly increased cytoplasmic and nuclear β-catenin levels24. Unpublished 
findings in our lab have demonstrated that β-catenin nuclear translocation in DD may lead to its 
association with certain pro-fibrotic and pro-malignant genes, such as WT1 (encoding Wilm’s 
Tumour One). A high level of the WT1 protein is known to be a common characteristic among 
various cancers, and more recently, in DD8, 9. The potential consequences of aberrant β-catenin 
nuclear translocation in DD, therefore, make it a valuable therapeutic target to prevent disease 
progression and/or recurrence. However, the specific molecular mechanisms that are responsible 
for its nuclear translocation are unclear.   
 
 
 
 
 
 
 
 
 
Fig 1. The normal wound healing process.  
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Mechanisms behind the nuclear translocation of β-catenin  
Recently, the conjugation of small ubiquitin-like modifiers (SUMO1) to Transducin β-
like 1 (TβL1) and Transducin β-like receptor 1 (TβLR1) have been implicated in the nuclear 
translocation of β-catenin in colon cancer cells exhibiting high β-catenin levels and aberrant β-
catenin signaling. More specifically, it is believed that only after SUMO1 conjugation 
(SUMOylation) of the TβL1/TβLR1 complex will β-catenin associate with the complex and 
localize into the nucleus10 (Figure 2). Small molecule inhibitors, such as BC2059 (Tegavivint), 
have been developed to competitively inhibit SUMOylated TβL1/TβLR1 interactions with β-
catenin as an anti-cancer therapeutic11, and are already in phase I clinical trials28. The aim of this 
study was to identify parallels in the molecular characteristics associated between DD and cancer 
to determine the feasibility of cross-purposing anti-cancer drugs such as BC2059 for the 
treatment of DD and other fibroproliferative disorders.  
 
Based on the findings that there are increased levels of cytoplasmic and nuclear β-catenin 
in DD, we hypothesized that in DD, β-catenin nuclear translocation is facilitated by the 
SUMOylated TβL1/TβLR1 complex, and that inhibition of this complex will prevent DD 
progression and recurrence.  
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Fig 2. Nuclear translocation of β-catenin in cancer.  
 
TβL1/TβLR1 SUMOylation induces their dissociation from the Nuclear hormone receptor Co-
Repressor (NCoR) / Silencing Mediator of Retinoic acid and Thyroid hormone receptor (SMRT) 
complex and translocation to the cytoplasm.  Cytoplasmic stabilization of ß-catenin by Wnt 
promotes the formation of ß-catenin/SUMO-TßL1/SUMO-TßLR1 complexes, translocation to 
the nucleus and transactivation of gene transcription. Adapted from Choi et al., (2011). 
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Materials and Methods 
Clinical Specimen Collection 
 Surgically resected palmar fascia tissue samples were obtained from patients with 
Dupuytren’s Disease (DD) and patients undergoing surgery for carpal-tunnel release (CT) at the 
XXX hospital. All patients signed consent forms allowing their tissues to be used for research, 
and the XXX Research Ethics Board approved sample collection for Health Sciences Research 
involving Human Subjects (XXX). Lab numbers were assigned to samples prior to processing in 
order to meet patient de-identification and confidentiality agreements.  
 
Primary Cell Culture 
 DD fibroblasts were extracted from the palmar fascia of DD patients, while the palmar 
fascia from patients without any history of DD undergoing carpal tunnel release was used to 
extract phenotypically normal fibroblasts (CT fibroblasts) for use as allogeneic controls.  
Tissue samples were dissected and placed onto 100 mm culture dishes containing α-MEM 
medium (Life Technologies) supplemented with 1% antibiotic-antimycotic solution (Life 
Technologies), 1% L-Glutamine (Life Technologies), and 10% fetal bovine serum (FBS; Life 
Technologies) at 37°C in 5% CO2. The cellular outgrowths from tissue fragments were then 
passaged routinely by trypsinization using 0.25% trypsin (Gibco). All primary cell cultures were 
used up to a maximum of seven passages, where afterward they were discarded.  
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Cytokine Treatments  
 DD and CT fibroblasts were seeded at a density of 2.2 x 106 cells in 100 mm dishes and 
serum-starved in serum-free α-MEM media for at least 24 hours prior to treatment with human 
pro-inflammatory cytokine mixtures (Cytomix 1), or human anti-inflammatory cytokine mixtures 
(Cytomix 2). The human cytokines comprising Cytomix 1 and 2 were purchased from 
PeproTech. Cytomix 1 was comprised of tumour necrosis factor (TNF), interleukin 1 beta (IL1-
β), and interferon gamma (IFN-γ) at a stock concentration of 1 ug/mL. Cytomix 2 was comprised 
of intereukin-4 (IL-4), interleukin 10 (IL-10), and transforming growth factor beta (TGFβ1), at a 
stock concentration of 1 ug/mL. DD and CT fibroblasts were treated separately at 24 and 48h 
with Cytomix 1 or Cytomix 2, at a dose of 0.5 ng/ml.  
 
Antibodies 
 The following primary antibodies were used: rabbit polyclonal SUMO1 antibody 
(ab11672, Abcam, 1:100 for proximity ligation assays), mouse monoclonal TβL1 antibody (sc-
137083, SantaCruz 1:150 for immunocytofluorescence and proximity ligation assays), mouse 
monoclonal TβLR1 antibody (ab117761, Abcam, 1:150 for immunocytofluorescence and 
proximity ligation assays), rabbit monoclonal non-phosphorylated active β-catenin antibody 
(D13A1, Cell Signalling Technology, 1:1000 for immunoblotting; 1:200 for proximity ligation 
assays). The following secondary antibodies for western immunoblotting were used: horseradish 
peroxidase (HRP)-linked horse anti-mouse IgG (#7076, Cell Signaling Technology, 1:1000), and 
HRP-linked goat anti-rabbit IgG (#7074, Cell Signaling Technology, 1:1000). For 
	 12	
immunocytofluorescence, the following secondary antibodies were used: anti-rabbit Alexa Fluor 
568 (Molecular Probes, 1:400) and anti-mouse Alexa Fluor 488 (Molecular Probes, 1:400). 
Cell Lysate Preparation 
 Cell pellets stored at -80°C were resuspended in RIPA cell lysis buffer (Teknova) 
supplemented with protease inhibitor cocktail (Sigma-Aldrich), 0.1M sodium flouride, 10 mM 
sodium orthovanadate, and 10 mM phenylmethane sulfonyl fluoride (PMSF). Resuspended cells 
were then needle aspirated five times and placed on ice for 30 minutes. Cell lysates were 
centrifuged at 5000 RPM to remove insoluble material, and total protein concentrations were 
determined by Bicinchoninic Assay (BCA, ThermoScientific). Protein lysates were used directly 
for western immunoblotting.  
 
Western Immunoblotting and Densitometry Analysis 
 Protein samples were separated using stain-free Mini Protean TGX precast gels (Bio-
Rad), and transferred onto a nitrocellulose membrane using the Invitrogen iBlot. Membranes 
were visualized by chemiluminescence on a Chemidoc XRS+ (BioRad). Band intensity was 
normalized using total protein lane quantification, using the total protein imaged on the stain-free 
membrane25. Relative densitometry analysis was performed using ImageLab 6.0 (BioRad).  
 
Immunocytofluorescence 
 Cells were fixed with 4% paraformaldehyde using Nunc Lab-Tek 8-well chamber slides 
(ThermoFisher) at 60-70% confluency. Cells were washed with phosphate-buffered saline (PBS) 
three times for five minutes and permeabilised by incubating in 0.1% Triton X-100 in PBS for 30 
minutes. Samples were blocked for ten minutes (Background Sniper, Biocare Medical) and then 
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rinsed three times for five minutes in PBS. All incubations were completed at room temperature. 
Primary antibodies were then added for overnight incubation at 4°C. Alexa Fluor 488 or 568 
secondary antibodies were added to the cells for one hour in PBS containing 1% bovine serum 
albumin (BSA) and 0.1% Tween-20 detergent, and subsequently washed in PBS for three times 
for five minutes in PBS. Glass slides were then mounted onto the chamber slides with Duolink 
mounting media containing DAPI counterstain (Sigma-Aldrich).  
Images were captured on a Nikon A1R+ hybrid resonant/galvano point scanning confocal 
microscope 20X objective lens, using the NIS Elements AR software for data acquisition at room 
temperature. The Alexa Fluor 568 was excited with the 15 MW 561 nm diode-pumped solid-
state laser, while the Alexa Fluor 488 was excited with the 15 MW 488 nm diode laser. The 
DAPI signal was excited using the 15 MW 405 nm diode laser. The system is equipped with four 
Photomultiplier tubes for standardized fluorescence detection.  
 
Proximity Ligation Assays (PLA) 
Cells were fixed with 4% paraformaldehyde using Nunc Lab-Tek 8-well chamber slides 
(ThermoFisher) at 60-70% confluency. Cells were washed with phosphate-buffered saline (PBS) 
three times for five minutes and permeabilised by incubating in 0.1% Triton X-100 in PBS for 30 
minutes. Cells were then rinsed with three times for five minutes in PBS and then treated with 
blocking solution (Duolink Sigma-Aldrich) for 60 minutes at 37°C. All incubations were 
completed at room temperature. Primary antibodies were then added for overnight incubation at 
4°C. Combinations of each primary antibody are as follows: i) β-catenin rabbit polyclonal Cell-
Signalling technology 9562L (1:200) and TβL1 mouse monoclonal Santa Cruz H-11 (1:100), ii) 
β-catenin rabbit polyclonal Cell-Signalling technology 9562L (1:200) and TβLR1 mouse 
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monoclonal Abcam 117761 (1:200), iii) TβL1 mouse monoclonal Santa Cruz H-11 (1:100) and 
SUMO1 rabbit polyclonal Abcam 11672 (1:400), iv) TβLR1 mouse monoclonal Abcam 117761 
(1:200) and SUMO1 rabbit polyclonal Abcam 11672 (1:400). The secondary probes were diluted 
1:5 in the antibody diluent (Duolink Sigma-Aldrich) and incubated for one hour at 37°C. The 
species of the secondary probes used were Anti-Rabbit PLUS and Anti-mouse MINUS (Duolink 
Sigma-Aldrich). The subsequent ligation and amplification reactions were performed according 
to the manufacturer’s instructions. Cells were then mounted on slides with mounting media 
containing DAPI counterstain (Sigma-Aldrich). 
Images were captured on a Nikon A1R+ hybrid resonant/galvano point scanning confocal 
microscope 60X objective lens, using the NIS Elements AR software for data acquisition. Five 
regions were randomly selected per slide and Z-stack images were captured for quantitative 
analysis 
 
Three-Dimensional Analysis of PLA Signals 
The 3D analysis was performed using NIS Elements AR software. The default 3D-
thresholding function was used to create an iso-surface of the nuclear (DAPI) signals. The PLA 
signals were then iso-surfaced using the default 3D spot-detection function. PLA interactions per 
cell were calculated by dividing the total number detected PLA signals by the number of cells in 
each image (based on DAPI signal).  
 
Statistical Analyses  
 Statistical analyses were conducted using GraphPad Prism 7 statistical software. For the 
immunoblotting experiments, ordinary one-way Analysis of Variance (ANOVA) was used in 
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order to determine any significant treatment effects at similar time points for the immunoblotting 
experiments, where significance was designated at p < 0.05. When significance was detected, 
post-hoc analyses were performed using the Dunnett’s test to compare the effect of each 
treatment at a specific time point with a control group at the same time point. For the PLA 
experiments, the unpaired T-test was used to determine any significant treatment effects between 
treatment and control, where significance was designated at p < 0.05.  
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Results 
Fibrosis-associated cytokines enhance β-catenin protein levels in DD and CT fibroblasts 
As with other fibroproliferative disorders, DD is the result of an exaggerated, abnormal 
wound healing response to chronic inflammation7. Therefore, we created cell culture conditions 
that would best mimic the chronic inflammatory environment in order to maximize and stabilize 
β-catenin levels.  
To mimic the pro-inflammatory phase of tissue repair, in which chronic activation is 
associated with cytotoxicity and damage 14, we treated DD and CT fibroblasts with a pro-
inflammatory cytokine mixture consisting of TNF (tumour necrosis factor), IL1β (interleukin-1 
beta), IFNγ (interferon gamma), termed “Cytomix 1”. To mimic the anti-inflammatory phase of 
tissue repair, where inflammation is dampened and tissue remodeling is initiated 14, we treated 
DD and CT fibroblasts with an anti-inflammatory cytokine mixture consisting of IL4 (interleukin 
4), IL10 (interleukin 10), and TGFβ (transforming growth factor beta), termed “Cytomix 2”. The 
concentrations of our cytokine mixtures were dosed at 0.5 ng/ml, approximating the 
physiological levels detected in fresh DD tissue15. There were no noticeable differences in the 
levels of active β-catenin when treated with Cytomix 1 and 2 at 24 hours, in both DD and CT 
fibroblasts (Figure 3B, 4B, respectively). A modest 2-fold increase in β-catenin levels was 
observed after Cytomix 1 treatment at 48 hours in DD fibroblasts (Figure 3D), however CT 
fibroblasts remained relatively unaffected (Figure 4D). After 48-hour Cytomix 2 treatment, we 
observed in DD fibroblasts significant 3-fold increase in β-catenin levels (Figure 3D), and a 
significant 2-fold increase in β-catenin levels in CT fibroblasts (Figure 4D). Taken together, 
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exposing DD and CT fibroblasts to Cytomix 2 successfully increased β-catenin levels, relative to 
Cytomix 1 treatments. 
 
   
 
 
 
 
 
 
 
 
Fig 3. Anti-inflammatory cytokines (Cytomix 2) increase levels of β-catenin in DD 
fibroblasts. 
 
(A, C) Immunoblots for active non-phosphorylated (Ser33/37/Thr41) β-catenin in DD 
fibroblasts. All groups were treated cultured in serum-free media for 24 hours prior to treatment. 
Treatments: no treatment for 24 hours or 48 hours (NT); TNF, IL1β, IFNγ (Cytomix1) (0.5 
ng/ml) added for 24 or 48 hours; IL4, IL10, TGFβ1 (Cytomix2) (0.5 ng/ml) added for 24 or 48 
hours. Total protein imaged on the stain-free membrane was used as a loading control to 
normalize band intensity. Results are shown from the same probed blot.  
 
(B, D) Relative densitometry analysis for active β-catenin in DD fibroblasts treated with 
Cytomix 1 or 2 at 24 and 48 hours, respectively. Data derived from one patient (N=1) assessed in 
triplicate (n=3). Total lane protein quantification was used to normalize band intensity. 
Densitometry analysis was tested by one-way ANOVA followed by Dunnett’s multiple 
comparison test. Asterisks indicate significant differences to control (*P<0.05, *** P<0.0002). 
Values shown are mean +/- SD. 
 
 
 
 
 
 
- 92 kDa - 92 kDa 
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Fig 4. Anti-inflammatory cytokines increase levels of β-catenin in CT fibroblasts. 
 
(A, C) Immunoblots for active non-phosphorylated (Ser33/37/Thr41) β-catenin in CT 
fibroblasts. All groups were cultured in serum-free media for 24 hours prior to treatment. 
Treatments: no treatment for 24 hours or 48 hours (NT); TNF, IL1β, IFNγ (Cytomix1) (0.5 
ng/ml) added for 24 or 48 hours; IL4, IL10, TGFβ1 (Cytomix2) (0.5 ng/ml) added for 24 or 48 
hours. Total protein imaged on the stain-free membrane was used as a loading control to 
normalize band intensity. Results are shown from the same probed blot. 
 
(B, D) Relative densitometry analysis for active β-catenin in CT fibroblasts treated with Cytomix 
1 or 2 at 24 and 48 hours, respectively. Data derived from one patient (N=1) assessed in triplicate 
(n=3). Total lane protein quantification was used to normalize band intensity. Densitometry 
analysis was tested by one-way ANOVA followed by Dunnett’s multiple comparison test. 
Asterisks indicate significant differences to control (*P<0.05, *** P<0.0002). Values shown are 
mean +/- SD. 
 
 
- 92 kDa - 92 kDa 
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Cytoplasmic localizations of TβL1 are increased in DD fibroblasts relative to CT fibroblasts  
To assess whether the SUMOylated TβL1/TβLR1 complex facilitates β-catenin nuclear 
translocation in DD fibroblasts, the cytoplasmic localization of TβL1 was visualized using 
immunofluorescence confocal microscopy. Primary mouse monoclonal antibodies to TβL1 and 
Alexa Fluor 568 secondary antibodies were used to visualize the cytoplasmic and nuclear 
localization of TβL1 by immunofluorescence confocal microscopy. As demonstrated in Figure 
5A, both cytoplasmic and nuclear localization of TβL1 was evident in DD fibroblasts, while 
TβL1 localization was found to be predominantly nuclear in CT fibroblasts, as seen in Figure 5B.  
 
TβLR1 localization is cytoplasmic and nuclear in both DD and CT fibroblasts 
 To assess whether the SUMOylated TβL1/TβLR1 complex facilitates β-catenin nuclear 
translocation in DD fibroblasts, the cytoplasmic localization of TβLR1 was visualized using 
immunofluorescence confocal microscopy.  Primary mouse monoclonal antibodies to TβLR1 
and Alexa Fluor 568 secondary antibodies were used to visualize TβLR1 localization by 
confocal microscopy. As demonstrated by Figure 6A and 6B, TβLR1 localization was both 
cytoplasmic and nuclear in DD and CT fibroblasts, respectively. 
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Fig 5. TβL1 cellular localization is more cytoplasmic in DD fibroblasts relative to CT 
fibroblasts.   
 
(A, B) DD and CT fibroblasts, respectively, were stained with a mouse monoclonal anti-TβL1 
antibody and the secondary antibody Alexa Fluor anti-mouse 568. Images were captured by 
confocal microscopy using a 20X objective lens. Scale bars: 100 microns.  
 
 
 
 
 
 
 
 
A 
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Fig 6. TβLR1 cellular localization is cytoplasmic and nuclear in both DD and CT 
fibroblasts.   
 
(A, B) DD and CT fibroblasts, respectively, were stained with a mouse monoclonal anti-TβLR1 
antibody, and secondary antibody Alexa Fluor anti-mouse 568. Images were captured by 
confocal microscopy using a 20X objective lens. Scale bars: 100 microns.  
 
 
 
 
 
 
 
 
A 
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Cytokine treatments enhance PLA signals for SUMO1 and TβL1 in both DD and CT 
fibroblasts, but not for SUMO1 and TβLR1 
To assess whether the SUMOylated TβL1/TβLR1 complex is active in DD and CT 
fibroblast, and whether the formation of these complexes changes in response to anti-
inflammatory cytokines, we conducted PLAs to determine proximity (<40 nm) between TβL1 
and SUMO1, as well as TβLR1 and SUMO1 by confocal microscopy. To maximize and stabilize 
β-catenin levels and effectively simulate the tissue repair environment in vitro, DD and CT 
fibroblasts were treated with Cytomix 2 for 48 hours. PLA signals for TβL1 and SUMO1 were 
significantly increased in both DD and CT fibroblasts (P = 0.0002) upon treatment with Cytomix 
2 for 48 hours (Figure 7). However, PLA signals for TβLR1 and SUMO1 remained unchanged in 
both DD and CT fibroblasts upon treatment with Cytomix 2 for 48 hours (Figure 8).  
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Fig 7. Interactions between TβL1 and SUMO1 are increased in DD and CT fibroblasts in 
response to Cytomix 2.   
 
(A): Transducin β-like 1 (TβL1) and small ubiquitin-like modifier 1 (SUMO1) are visualized by 
proximity ligation assay (PLA). Representative images are shown where PLA signal (red) 
indicates close proximity (<40 nm) between two proteins. DD and CT fibroblasts were treated 
with Cytomix 2, consisting of interleukin-4, interleukin-10, and transforming growth factor-1 
beta. Images were captured by confocal microscopy using a 60X objective lens. Scale bars: 50 
microns.  
 
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test 
was performed to test for significance between control and Cytomix 2 treatment. Values shown 
are mean +/- SD.  
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Fig 8. Interactions between TβLR1 and SUMO1 are unchanged in DD and CT fibroblasts 
in response to Cytomix 2.   
 
(A): Transducin β-like receptor-1 (TβLR1) and small ubiquitin-like modifier 1 (SUMO1) are 
visualized by proximity ligation assay (PLA). Representative images are shown where PLA 
signal (purple) indicates close proximity (<40 nm) between two proteins. DD and CT fibroblasts 
were treated with Cytomix 2, consisting of interleukin-4, interleukin-10, and transforming 
growth factor-1 beta. Images were captured by confocal microscopy using a 60X objective lens. 
Scale bars: 50 microns.  
 
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test 
was performed to test for significance between control and Cytomix 2 treatment. Values shown 
are mean +/- SD.  
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Cytokine treatments enhance PLA signals for β-catenin and TβL1 as well as β-catenin 
and TβLR1 in both DD and CT fibroblasts 
 To assess whether the SUMOylated TβL1/TβLR1 complex is active in DD and CT 
fibroblasts, and whether these complexes interact with β-catenin, PLAs were conducted to 
determine proximity (<40 nm) between β-catenin and TβL1 as well as β-catenin and TβLR1 by 
confocal microscopy. To maximize and stabilize β-catenin levels and effectively simulate the 
tissue repair environment in vitro, DD and CT fibroblasts were treated with Cytomix 2 for 48 
hours.  PLA signals for TβL1 and β-catenin were significantly increased in both DD and CT 
fibroblasts in response to Cytomix 2 treatment for 48 hours (P = 0.0003) (Figure 9). PLA signals 
for TβLR1 and β-catenin were also significantly increased in both DD and CT fibroblasts in 
response to Cytomix 2 treatment for 48 hours (P< 0.02) (Figure 10).  
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Fig 9. Interactions between TβL1 and β-catenin are increased in DD and CT fibroblasts in 
response to Cytomix 2.   
 
(A): Transducin β-like 1 (TβL1) and β-catenin are visualized by proximity ligation assay (PLA). 
Representative images are shown where PLA signal (red) indicates close proximity (<40 nm) 
between two proteins. DD and CT fibroblasts were treated with Cytomix 2, consisting of 
interleukin-4, interleukin-10, and transforming growth factor-1 beta. Images were captured by 
confocal microscopy using a 60X objective lens. Scale bars: 50 microns.  
 
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test 
was performed to test for significance between control and Cytomix 2 treatment. Values shown 
are mean +/- SD.  
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Fig 10. Interactions between TβLR1 and β-catenin are increased in DD and CT fibroblasts 
in response to Cytomix 2.   
 
(A): Transducin β-like receptor-1 (TβLR1) and β-catenin are visualized by proximity ligation 
assay (PLA). Representative images are shown where PLA signal (red) indicates close proximity 
(<40 nm) between two proteins. DD and CT fibroblasts were treated with Cytomix 2, consisting 
of interleukin-4, interleukin-10, and transforming growth factor-1 beta. Images were captured by 
confocal microscopy using a 60X objective lens. Scale bars: 50 microns.  
 
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test 
was performed to test for significance between control and Cytomix 2 treatment. Values shown 
are mean +/- SD.  
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Discussion 
 In this study, we investigated whether any parallels existed with respect to abnormal β-
catenin signalling in DD relative to cancer, in order to assess the feasibility and potential of 
cross-purposing anti-cancer drugs to target β-catenin nuclear translocation in fibroproliferative 
diseases. We determined that the cellular localization of TβL1 and TβLR1 are primarily 
cytoplasmic in DD fibroblasts— translating into an increased availability for the formation of 
TβL1/TβLR1/β-catenin complexes that can then translocate into the nucleus relative to CT 
fibroblasts. Furthermore, in response to treatment with anti-inflammatory cytokines, DD and CT 
fibroblasts both demonstrated increased levels of SUMOylated TβL1 and TβLR1, as well as 
higher levels of TβL1 and TβLR1 interactions with β-catenin.  
 
To maximize and stabilize β-catenin levels, DD and CT fibroblasts were treated with 
fibrosis-associated cytokines to mimic chronic inflammation. DD fibroblasts demonstrated 
higher sensitivity to 48-hour Cytomix 1 treatment, as a modest two-fold increase in β-catenin 
levels was observed (Figure 3D) relative to CT fibroblasts (Figure 4D). As mentioned 
previously, DD is a hyperproliferative disorder resulting from an exaggerated, abnormal wound 
healing response to chronic inflammation7. The heightened sensitivity of DD fibroblasts to pro-
inflammatory cytokines in Figure 3D supports this hypothesis. In response to 48-hour Cytomix 2 
treatment, DD fibroblasts experienced a significant 3-fold increase in β-catenin levels (Figure 
3D), and CT fibroblasts experienced a significant 2-fold increase (Figure 4D). The increase in β-
catenin levels observed after Cytomix 2 treatment may be attributed to TGFβ, as previous studies 
determined that fibroblasts treated with TGFβ experienced an increase in β-catenin levels13, 17. 
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TGFβ is an important anti-inflammatory cytokine during the wound healing process and is linked 
to β-catenin signalling to modulate wound repair and tissue remodeling18.  
 
 We determined that upon treatment with Cytomix 2 —consisting of the anti-
inflammatory fibrosis-associated cytokines IL4, IL10, and TGFβ1— resulted in increased levels 
of SUMOylated TβL1 in DD and CT fibroblasts (Figure 7). Furthermore, interactions between 
TβL1 and TβLR1 with β-catenin were increased in DD and CT fibroblasts upon treatment with 
Cytomix 2 (Figures 9 & 10). To our knowledge, the facilitation of β-catenin nuclear translocation 
by the SUMOylated TβL1/TβLR1 has only been studied in the context of cancer cells. Our novel 
findings implicating β-catenin nuclear translocation by SUMOylated TβL1/TβLR1 have not yet 
been studied in the context of fibrosis and chronic inflammation. Based on these new findings, 
along with the role that TGFβ plays in modulating wound repair and tissue remodelling16, 17, 18 — 
we hypothesize that the anti-inflammatory cytokines IL4, IL10, and TGFβ1 may contribute to 
the transition between the inflammation and proliferation phases in both normal and fibrotic 
tissue repair. More specifically, the anti-inflammatory cytokines may lead to increased 
interactions between SUMOylated TβL1/TβLR1 and β-catenin, thereby resulting in the β-
catenin-mediated transactivation of genes involved in cellular proliferation and wound healing 
during normal and abnormal tissue repair (Figure 11).    
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Fig 11. The presence of anti-inflammatory cytokines during the transition from the inflammation 
to proliferation phase of wound healing mediates β-catenin nuclear translocation as a result of the 
SUMOylated TβL1/TβLR1 complex.  
 
 
Limitations and Future Directions  
 We have presented here evidence that SUMOylated TβL1 and SUMOylated TβLR1 exist 
at higher levels in both DD and CT fibroblasts upon treatment with anti-inflammatory cytokines, 
which correlates with increased protein levels of β-catenin. Additionally, TβL1 and TβLR1 
interactions with β-catenin are also more abundant as a result. PLAs were used to detect these 
protein-protein interactions, as this technique detects proximity between two proteins that is < 40 
nm. However, it is important to detect these interactions with other techniques such as 
immunoprecipitation, in order to validate our PLA findings. Additionally, in order to directly 
confirm the mechanisms behind BC-2059 and its specificity towards targeting specific β-catenin 
interactions with SUMOylated TβL1 and TβLR1 — it is important to test whether interactions 
between TβL1 and TβLR1 with β-catenin are effectively disrupted in drug-treated DD 
fibroblasts.   
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 The protein-protein interactions were primarily detected in fibroblasts cultured in vitro, 
and this may present a limitation of this study. Although the levels of β-catenin were stabilized 
through treatments with fibrosis-associated cytokines in order to mimic the tissue repair 
environment and maintain physiological relevance — these findings can be strengthened by 
moving towards an ex vivo experimental approach. Performing immunostaining and PLAs in 
fresh palmar fascia tissue ex vivo may strengthen our findings by providing increased 
physiological relevance 27.  
 
Conclusion 
 In summary, we have presented evidence of the specific mechanisms that may be 
involved in β-catenin nuclear translocation during the anti-inflammatory phase of tissue repair. 
Our novel findings present the SUMOylated TβL1/TβLR1 complex as a new therapeutic target 
for DD and other fibroproliferative diseases. Small molecule inhibitors such as BC2059 that 
disrupt interactions between SUMOylated TβL1/TβLR1 and β-catenin are in development for the 
treatment of cancer and are already undergoing phase-I clinical trials28. Our observations here 
show that similar mechanisms may be involved during the abnormal tissue repair process 
associated with the development of DD. At present, there are no therapies that focus on targeting 
early disease development and preventing post-surgical disease recurrence in DD.  The results of 
this study identify SUMOylated TβL1/TβLR1 interactions with β-catenin as a novel therapeutic 
target for DD and other fibroproliferative diseases.   
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